Abstracts tagged "clinical trial"

Abstract Number: 2285 • ACR Convergence 2024
Safety and Tolerability of a Combination of Curcumin, Omega-3 and Vitamin-D: Results from the PASCOD Study, an RA Prevention Protocol
Halle Cochrane, Caitlin Mcfadyen, Kale Mayor, Rhonda Silva, Kristin James, Xiaobo Meng, Dylan Mackay, Hani El-Gabalawy and Liam O'Neil, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Rheumatoid Arthritis (RA) is a progressive inflammatory autoimmune disease affecting 1% of the global population for which there is currently no cure. Recent research…
Abstract Number: 2515 • ACR Convergence 2024
Upadacitinib for Refractory Behçet’s Syndrome: A Multi-center, Prospective, Open-label, Pilot Study
Weiyi Xia¹, Jiachen Li¹, Tian Liu¹ and Yuhui Li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University, BeiJing, China
Background/Purpose: The aim of this prospective cohort study is to evaluate the efficacy and safety of Janus kinase (JAK) inhibitor upadacitinib in refractory Behçet’s Syndrome…
Abstract Number: 0376 • ACR Convergence 2024
Preliminary Results of the Ondansetron Pre-medication Trial in Juvenile Idiopathic Arthritis: A Pragmatic Randomized Controlled Trial Nested in the CAPRI Registry
Gaelle Chedeville¹, Heinrike Schmeling², Jean-Philippe Proulx-Gauthier³, Michelle Batthish⁴, Jean Jacques De Bruycker⁵, Brian Feldman⁶, Roberta A Berard⁷, Roxana Bolaria⁸, Amieleena Chhabra⁹, Lily Lim¹⁰, Adam Huber¹¹, Matthew Berkowitz¹², Thomas Loughin¹² and Jaime Guzman¹³, and CAPRI Registry Investigators, ¹The Montreal Children's Hospital, Montreal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³CHU de Quebec - Universite Laval, Quebec, QC, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada, ⁵UNIVERSITY OF MONTREAL, Montreal, QC, Montreal, QC, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁷London Health Sciences Centre, London, ON, Canada, ⁸Victoria Arthritis Center, Victoria, BC, Canada, ⁹University of British Columbia, Penticton, BC, Canada, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹IWK Health Centre, Halifax, NS, Canada, ¹²Simon Fraser University, Burnaby, BC, Canada, ¹³University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: About 50% of children with Juvenile Idiopathic Arthritis (JIA) receiving methotrexate (MTX) develop MTX intolerance with severe anticipatory nausea/vomiting and avoidance behaviors. Intolerance often…
Abstract Number: 0602 • ACR Convergence 2024
Bimekizumab Impact on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Core Domains for Patients with Psoriatic Arthritis: Results up to 2 Years of Treatment Duration
Joseph F. Merola¹, Philip Mease², Atul Deodhar³, Alice Gottlieb⁴, Barbara Ink⁵, Dirk de Cuyper⁶, Rajan Bajracharya⁵, Jérémy Lambert⁷, Jason Coarse⁸ and Laura Coates⁹, ¹UT Southwestern Medical Center, Dallas, TX, ²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁴Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Brussels, Belgium, ⁷UCB Pharma, Colombes, France, ⁸UCB Pharma, Morrisville, NC, ⁹University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom
Background/Purpose: The Group for Research and Assessment of Psoriasis and PsA (GRAPPA) domain‑based treatment recommendations for PsA focus on six key domains: peripheral arthritis, axial…
Abstract Number: 0774 • ACR Convergence 2024
A Multicenter, Randomized, Controlled Trial to Evaluate the Effects of Low-dose Glucocorticoids Compared to Stopping Glucocorticoids to Maintain Remission of Granulomatosis with Polyangiitis: The TAPIR Trial
Peter Merkel¹, Christian Pagnoux², Nader Khalidi³, Ulrich Specks⁴, Curry Koening⁵, Carol Langford⁶, Larry Moreland⁷, Paul Monach⁸, Jason Springer⁹, Shubhasree Banerjee¹, Simon Carette¹⁰, Rennie Rhee¹, Medha Soowamber¹¹, Kenneth Warrington⁴, Renee Borchin¹², Cristina Burroughs¹³, Carol McAlear¹, David Cuthbertson¹³ and Jeffrey Krischer¹³, ¹University of Pennsylvania, Philadelphia, PA, ²Mount Sinai Hospital, Toronto, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Mayo Clinic, Rochester, MN, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Colorado, Denver, CO, ⁸VA Boston Healthcare System, Boston, MA, ⁹Vanderbilt University Medical Center, Franklin, TN, ¹⁰Mount Sinai Hosptial, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, ON, Canada, ¹²University of South Florida, Tampa, ¹³University of South Florida, Tampa, FL
Background/Purpose: Use of low-dose glucocorticoids to maintain remission in patients with granulomatosis with polyangiitis (GPA) remains controversial. Additionally, there is no consensus on how to…
Abstract Number: 1194 • ACR Convergence 2024
Treatment Effect of Lorecivivint Across Multiple Trials in Patients with Knee OA: A Meta-analysis
Christopher Swearingen¹, Jeyanesh Tambiah² and Yusuf Yazici³, ¹Biosplice Therapeutics, Inc, San Diego, CA, ²Biosplice Therapeutics Inc., San Diego, CA, ³NYU Grossman School of Medicine, La Jolla, CA
Background/Purpose: Lorecivivint (LOR), an intra-articular (IA) CLK/DYRK inhibitor thought to modulate inflammatory and Wnt pathways has previously appeared safe, improved patient-reported outcomes (PROs) compared with…
Abstract Number: 1467 • ACR Convergence 2024
Time to First Clinically Meaningful Efficacy Responses in Musculoskeletal and Patient Reported Outcomes in Patients with Active Psoriatic Arthritis Treated with Risankizumab: A Post Hoc Analysis of the Phase 3 KEEPsAKE 1 and KEEPsAKE 2 Trials
William Tillett¹, Simona Rednic², Kristi Mizelle³, Christopher Ritchlin⁴, Saakshi Khattri⁵, Linyu Shi⁶, Brenton Bialik⁶, Thomas Iyile⁷ and Arthur Kavanaugh⁸, ¹Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ²Department of Rheumatology, "Iuliu Hațieganu" University of Medicine and Pharmacy and County Emergency Hospital, Cluj-Napoca, Romania, ³Tidewater Physicians Multispecialty Group (TPMG) Rheumatology, Newport News, VA, ⁴Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁵Mount Sinai Medical Center, New York, NY, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., hyattsville, MD, ⁸University of California San Diego, La Jolla, CA
Background/Purpose: The phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized double-blind clinical trials demonstrate that risankizumab (RZB) provides a high level of durable improvement in…
Abstract Number: 1677 • ACR Convergence 2024
Safety and Efficacy of FNS007, a Non-T Cell Receptor Contacting Peptide, for Patients with Active Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial
Ru Li¹, Xing Sun¹, Suping Niu², Xiaolin Sun¹, Guimin Zheng³, Meilu Liu³, Jiyang Lv⁴, Gengmin Zhou⁴, Gang Yuan⁵, Yujin Ye⁵, Shuang Wang⁵, Pingfei Fang⁶, Qi Tang⁶, Jin Kang⁶, Xiaoyue Li⁷, Chao Sun⁷, Song Zhang⁷, Yongjun Mei⁷, Jian Wang⁷, He Su⁷, Lijing Huang⁸, Chenhui Li⁸, Chao Liu⁸, Fengxiao Zhang³, Qingwen Wang⁴, Niansheng Yang⁵, Fen Li⁶, Linjie Chen⁷, Yi Fang² and Zhanguo Li⁹, ¹Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China, ²Clinical Trial Institution, Peking University People’s Hospital, Beijing, China, ³Department of Rheumatology and Immunology, Hebei General Hospital, Shijiazhuang, Hebei, China (People's Republic), ⁴Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China (People's Republic), ⁵Department of Rheumatology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China (People's Republic), ⁶Department of Rheumatology and Immunology, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China (People's Republic), ⁷Department of Rheumatology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ⁸Hebei Fitness Biotechnology Limited Company, Shijiazhuang, Hebei, China (People's Republic), ⁹Peking univeristy people's hospital, Beijing, China
Background/Purpose: Long-term drug-free remission is an unmet need for the management of rheumatoid arthritis (RA), which might be achieved by restoring antigen-specific immune tolerance. Autoantigenic…
Abstract Number: 2019 • ACR Convergence 2024
Safety and Efficacy of SEL-212 in the US and ex-US Subgroups: Results from the Phase 3 DISSOLVE Studies
Michael Pillinger¹, Alan Kivitz², Atul Singhal³, Anand Patel⁴, Rehan Azeem⁵, Aletta Falk⁶, Bhavisha Desai⁷, Hugues Santin-Janin⁸ and Herbert Baraf⁹, ¹New York University Grossman School of Medicine, New York,, NY, ²Altoona Center for Clinical Research, Duncansville, PA, ³Southwest Arthritis Research Group, Mesquite, TX, ⁴Conquest Research, Winter Park, FL, ⁵Sobi Inc., Waltham, MA, ⁶Sobi, Stockholm, Sweden, ⁷Sobi, Glastonbury, CT, ⁸Sobi, BETTENDORF (68560), France, ⁹Center for Rheumatology and Bone Research, Wheaton, MD
Background/Purpose: The DISSOLVE Phase 3 study program investigated the efficacy and safety of SEL-212, a novel, once-monthly, two-component infusion therapy consisting of pegadricase (SEL-037, a…
Abstract Number: 2286 • ACR Convergence 2024
Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials
Josef Smolen¹, Gerd Burmester², Yoshiya Tanaka³, Tsutomu Takeuchi⁴, Jeffrey Curtis⁵, Ted Mikuls⁶, Clementina López Medina⁷, Peter C. Taylor⁸, Nicola Tilt⁹, Bernard Lauwerys¹⁰, Baran Ufuktepe¹¹ and Thomas Huizinga¹², ¹Medical University of Vienna, Vienna, Austria, ²Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁴Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁵The University of Alabama at Birmingham, Birmingham, AL, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Reina Sofia University Hospital, Cordoba, Spain, ⁸University of Oxford, Oxford, United Kingdom, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Istanbul, Turkey, ¹²Department of Rheumatology, Leiden University, Leiden, Netherlands
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), including those treated with disease-modifying antirheumatic drugs, high rheumatoid factor (RF) levels are a poor prognostic factor,…
Abstract Number: 2527 • ACR Convergence 2024
Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS)
Jacques-Eric Gottenberg¹, Kathy Sivils², Kim Campbell³, Jada Idokogi³, Kim Lo³, Sophia G. Liva³, Jonathan Shelton⁴, Harman Dhatt⁵, Jonathan J. Hubbard³ and Ghaith Noaiseh⁶, ¹Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ²Johnson & Johnson Innovative Medicine, Edmond, OK, ³Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, ⁴Janssen Scientific Affairs, LLC, San Diego, CA, USA, San Diego, ⁵Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, USA, Raritan, NJ, ⁶University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by the presence of specific autoantibodies (AAb) and lymphocytic infiltration of exocrine glandular tissues.…
Abstract Number: 0405 • ACR Convergence 2024
Olokizumab, a Monoclonal Antibody Against IL-6, in Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA): Results of 24 Weeks of the Phase 2 Open-label Clinical Trial
Ekaterina Alexeeva¹, Tatiana Dvoryakovskaya², Elena Zholobova³, Elizaveta Krekhova⁴, Rinat Raupov⁵, Daria Bukhanova⁶, Alina Egorova⁶, Sofia Kuzkina⁶, Mikhail Samsonov⁶, Irina Nikishina⁷ and Mikhail Kostik⁵, ¹National Medical Research Center of Children's Health, Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ²National Medical Research Center of Children's Health, Moscow, Russia, ³Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ⁴National Medical Research Centre for Children's Health, Moscow, Russia, ⁵Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ⁶R-Pharm, Moscow, Russia, ⁷V. A. Nasonova Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: Olokizumab (OKZ) is a direct interleukin-6 inhibitor for treatment of rheumatoid arthritis and is being investigated in the open-label Phase 2 trial in adolescents…
Abstract Number: 0610 • ACR Convergence 2024
Clinical Evaluation on IFI44L Gene Methylation Detection for Diagnosis of Systemic Lupus Erythematosus by Methylation Sensitive High Resolution Melting (MS-HRM)
Xiaoping hong and liancheng lin, The Second Clinical Medical College of Jinan University, Shenzhen, China (People's Republic)
Background/Purpose: To evaluate the clinical effectiveness of IFI44L gene methylation detection for the diagnosis of Systemic Lupus Erythematosus (SLE) by MS-HRM, to determine the relative…
Abstract Number: 0775 • ACR Convergence 2024
A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab in IgG4-Related Disease (MITIGATE): Primary Efficacy and Safety Findings
John Stone¹, Emma Culver², Arezou Khosroshahi³, Wen Zhang⁴, Emanuel Della Torre⁵, Kazuichi Okazaki⁶, Yoshiya Tanaka⁷, Matthias Löhr⁸, Nicolas Schleinitz⁹, Lingli Dong¹⁰, Hisanori Umehara¹¹, Marco Lanzillotta¹², Zachary Wallace¹³, Mikael Ebbo¹⁴, George Webster¹⁵, Ferran Martinez Valle¹⁶, Manu Nayar¹⁷, Vinciane Rebours¹⁸, Cory Perugino¹⁹, Xinxin Dong²⁰, Yanping Wu²⁰, Nishi Rampal²⁰ and Daniel Cimbora²⁰, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²John Radcliffe Hospital, and Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, ³Emory University, Atlanta, GA, ⁴Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁵Ospedale San Raffaele, Milan, Italy, ⁶University of Occupational and Environmental Health, Osaka, Japan, ⁷Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁸Karolinska Institutet, Stockholm, Sweden, ⁹Aix Marseille university, AP-HM, Marseille, France, ¹⁰Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic), ¹¹Department of Rheumatology and Immunology, Nagahama City Hospital,, Nagahama, Shiga 526-0043, Japan, Japan, ¹²IRCCS Ospedale San Raffaele, Milano, Italy, ¹³Massachusetts General Hospital, Newton, MA, ¹⁴Aix-Marseille Université, Marseille, France, ¹⁵University College Hospital London, London, United Kingdom, ¹⁶Vall d’Hebron Hospital, Barcelona, Spain, ¹⁷Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ¹⁸Beaujon Hospital, Université Paris-Cité, France, ¹⁹Massachusetts General Hospital, Boston, MA, ²⁰Amgen Inc., Thousand Oaks, CA
Background/Purpose: IgG4-related disease (IgG4-RD) is a rare, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…
Abstract Number: 1211 • ACR Convergence 2024
An Evaluation of the Efficacy, Pharmacokinetics and Safety, of the Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist RTX-GRT7039 – a Placebo-controlled Study in Patients with Osteoarthritis Knee Pain
Thor Ostenfeld¹, Stefan Ivanicius¹, Roman Stancik² and Philip G Conaghan³, ¹Grunenthal GmbH, Aachen, Germany, ²National Institute of Rheumatic Diseases, Piestany, Slovenia, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: The transient receptor potential vanilloid 1 (TRPV1) is a critical driver of osteoarthritis (OA) pain. RTX-GRT7039 is an investigational medicinal product containing the active…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].